Press Release Details

BERKELEY, CA -- (Marketwired) -- 03/08/16 --  Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2015.

The Company had $196.1 million in cash, cash equivalents and marketable securities as of December 31, 2015.

Total revenues for the year ended December 31, 2015, decreased by $7.0 million or 63 percent compared to the same period in 2014, primarily due to a $5.2 million decrease in collaboration revenue due to winding down of work performed for the AZD1419 program and expiration of our collaboration agreement with GSK in 2014.

Operating expenses increased by $6.8 million or seven percent during 2015 compared to 2014, primarily due to costs related to HBV-23, the Phase 3 clinical study of HEPLISAV-B™ completed in October 2015, preparation for the commercial launch of HEPLISAV-B in the United States and clinical trial expense for SD-101, Dynavax's cancer immunotherapeutic product candidate.

The net loss allocable to common stockholders for the year ended December 31, 2015 was $106.8 million, or $3.25 per share, compared to $90.7 million, or $3.45 per share for the year ended December 31, 2014.

"During 2015, we completed HBV-23 and significantly strengthened the Company's cash position. Earlier this year we reported that this third pivotal study had met both co-primary endpoints. We plan to resubmit the HEPLISAV-B BLA (Biologics License Application) to the FDA by the end of this month. Based on our expectation of a six-month review, if our application is approved we expect to launch this product in the fourth quarter of this year," said Eddie Gray, chief executive officer of Dynavax.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information visit www.dynavax.com.

Forward Looking Statements

This release contains forward-looking statements, including statements regarding expected timing of the HEPLISAV-B BLA resubmission, possible approval, and expected launch. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether there will be the need for additional studies, further manufacturing enhancements or other activities, or other issues will arise that will delay the BLA resubmission and/or negatively impact the acceptance, review, duration of review and approval of the BLA by the FDA; whether we will successfully launch the product, possible claims against us, including enjoining sales of HEPLISAV-B based on the patent rights of others, and the potential size and value of approved indications addressable with HEPLISAV-B; initiation and completion of pre-clinical studies and clinical trials of our other product candidates, including SD-101, in a timely manner; the results of clinical trials and the impact of those results on the initiation or continuation of subsequent trials and issues arising in the regulatory process; achieving the objectives of and maintaining our collaborative and licensing agreements; our ability to execute on our commercial strategies; whether our financial resources will be adequate without the need to obtain additional financing and other risks detailed in the "Risk Factors" section of our most recent current periodic report filed with the SEC. These statements represent our estimates and assumptions only as of the date of this release. We do not undertake any obligation to update publicly any such forward-looking statements, even if new information becomes available.

DYNAVAX TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
			Three Months Ended				Years Ended
			December 31,				December 31,
			2015		2014		2015		2014
Revenues:
	Collaboration revenue		$535		$1,734		$2,765		$7,933
	Grant revenue		75		142		683		2,688
	Service and license revenue		75		401		602		411
Total revenues			685		2,277		4,050		11,032
Operating expenses:
	Research and development		20,932		19,638		86,943		84,580
	General and administrative		6,699		5,052		22,180		17,377
	Unoccupied facility expense		--		--		--		386
Total operating expenses			27,631		24,690		109,123		102,343
Loss from operations			(26,946)		(22,413)		(105,073)		(91,311)
Interest income			127		29		205		191
Interest expense			--		(35)		(572)		(35)
Other income (expense), net			(43)		133		317		433
Loss on extinguishment of debt			--		--		(1,671)		--
Net loss			(26,862)		(22,286)		(106,794)		(90,722)
Preferred stock deemed dividend			--		--		--		--
Net loss allocable to common stockholders			($26,862)		($22,286)		($106,794)		($90,722)
Basic and diluted net loss per share allocable to common stockholders			($0.70)		($0.85)		($3.25)		($3.45)
Shares used to compute basic and diluted net loss per share allocable to common stockholders			38,429		26,298		32,881		26,289

DYNAVAX TECHNOLOGIES CORPORATION
SELECTED BALANCE SHEET DATA
(In thousands)
(Unaudited)
			December 31,		December 31,
			2015		2014
Assets
	Cash, cash equivalents and marketable securities		$ 196,125		$ 122,652
	Property and equipment, net		13,804		7,924
	Goodwill		2,043		2,277
	Other assets		4,661		5,437
Total assets			$ 216,633		$ 138,290
Liabilities and stockholders' equity
	Deferred revenues		$ 2,654		$ 12,765
	Other liabilities		26,900		15,484
	Long-term debt		--		9,559
	Total liabilities		29,554		37,808
	Stockholders' equity		187,079		100,482
Total liabilities and stockholders' equity			$ 216,633		$ 138,290

Contact:
Michael Ostrach
Chief Financial Officer
510-665-7257
Email contact

Source: Dynavax Technologies

News Provided by Acquire Media